Alectinib-induced Hemolytic Anemia with Positive Direct Antiglobulin Test in a Patient with Lung Adenocarcinoma: A Possible Drug-Drug Interaction Effect-Reference-Cited by-同舟云学术

Alectinib-induced Hemolytic Anemia with Positive Direct Antiglobulin Test in a Patient with Lung Adenocarcinoma: A Possible Drug-Drug Interaction Effect

Published:2023 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Isomura Yuta¹,Tamiya Hiroyuki¹

Affiliation:

1. Department of Internal Medicine, Tokushima Prefectural Miyoshi Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_1286-22/_pdf

Reference14 articles.

1. 1. Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390: 29-39, 2017.

2. 2. ALECENSA^® Interview form, 11th ed., 2020. Chugai Pharmaceutical Co., Ltd. Ed [Internet]. [cited 2022 Oct 30]. Available from: https://chugai-pharm.jp/content/dam/chugai/product/alc/cap/if/doc/alc_if.pdf (in Japanese). Tokyo.

3. 3. Okumoto J, Sakamoto S, Masuda T, et al. Alectinib-induced Immune Hemolytic anemia in a patient with Lung adenocarcinoma. Intern Med 60: 611-615, 2021.

4. 4. Li THS, Chik YKJ, Wong WS. Alectinib-induced red cell morphological changes in a patient with underlying α-thalassaemia trait. Int J Lab Hematol 44: 65-66, 2022.

5. 5. Yuan Y, Mapp S, Xu W. Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor. Br J Haematol 190: 642, 2020.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alectinib/famotidine interaction;Reactions Weekly;2023-08-05

2. Drug Interaction-induced Hemolytic Anemia: An Unresolved Diagnostic Process;Internal Medicine;2023